Xilio Therapeutics (XLO) Gains from Investment Securities (2025 - 2026)

Xilio Therapeutics (XLO) posted Gains from Investment Securities of -$3.3 million for Q1 2026, up 84.49% sequentially from -$21.3 million in Q4 2025.

Xilio Therapeutics (XLO) Gains from Investment Securities (2025 - 2026) Analysis & Trends

Xilio Therapeutics has reported Gains from Investment Securities for 2 years, with the latest figure at -$3.3 million in Q1 2026.

Quarterly Gains from Investment Securities changed N/A year-over-year to -$3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.1 million (changed N/A YoY) and the FY2025 annual result came in at -$5.8 million, changed N/A from the prior year.
Gains from Investment Securities advanced to -$3.3 million in Q1 2026 per XLO's latest filing, from -$21.3 million in the prior quarter.
Over five years, Gains from Investment Securities peaked at $15.4 million in Q3 2025 and troughed at -$21.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Xilio Therapeutics	178.33 Mn	42.29 Mn	-

Download Data